<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543062</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-001-102</org_study_id>
    <secondary_id>20 July 2007</secondary_id>
    <nct_id>NCT00543062</nct_id>
  </id_info>
  <brief_title>Staccato Prochlorperazine Thorough QT/QTc</brief_title>
  <official_title>Thorough QT/QTc Study of Staccato® Prochlorperazine for Inhalation in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety of Staccato Prochlorperazine on cardiac repolarization (QTc interval
      duration) at 2 dose levels compared to placebo in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The planned study is a single dose, double-blind, double-dummy, active and placebo
      controlled, randomized, 4-period cross-over study investigating investigating 2 doses levels
      of Staccato Prochlorperazine, a positive control with known QT/QTc prolongation (oral
      moxifloxacin), and placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Female and male subjects in approximately equal numbers were randomly assigned (1:1:1:1) to receive the 4 treatment sequences</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This was a double-blind, double dummy, placebo controlled, randomized 4-period crossover study to assess the effects of single doses of 5 and 10 mg of Staccato Prochlorperazine on QT intervals.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Effect of Inhaled Prochlorperazine on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo</measure>
    <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 22 hr</time_frame>
    <description>Time-matched differences in QTcI values between the maximum of the mean difference from baseline of the QTcI interval after time-matched placebo subtraction for treatment at 11 post-inhalation times.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTcI Versus Prochlorperazine Concentration</measure>
    <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 22 hr</time_frame>
    <description>QTcI @ median prochlorperazine concentration (3.75 mcg/mL) based on linear and nonlinear regression of QTcI versus time matched serum prochlorperazine concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers and % of Subjects With QTcI &gt; 450 ms</measure>
    <time_frame>24 hours</time_frame>
    <description>Numbers and Percents of Subjects with QTcI exceeding 450 ms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers and % of Subjects With QTcI &gt; 480 ms</measure>
    <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 22 hr</time_frame>
    <description>Numbers and Percents of Subjects with QTcI exceeding 480 ms at any of the outcome measure time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers and % of Subjects With QTcI Change &gt; 30 ms</measure>
    <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 22 hr</time_frame>
    <description>Numbers and Percents of Subjects with QTcI increase from baseline exceeding 30 ms at any of the outcome measure time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers and % of Subjects With QTcI Change &gt; 60 ms</measure>
    <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 22 hr</time_frame>
    <description>Numbers and Percents of Subjects with QTcI increase from baseline exceeding 60 ms at any of the outcome measure time points</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Maximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity)</measure>
    <time_frame>1, 1.5, 2, 2.5, 3, 5 hours</time_frame>
    <description>A thorough QT/QTc study may be considered to have demonstrated assay sensitivity if 1 or more of the lower 95% CI values exceeds 5 msec</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Cardiotoxicity</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence ABCD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment Sequence ABCD where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence BDAC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment Sequence BDAC where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence CABD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment Sequence CABD where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence DCBA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment Sequence DCBA where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled placebo</intervention_name>
    <description>Inhaled Staccato placebo (0 mg)</description>
    <arm_group_label>Treatment Sequence ABCD</arm_group_label>
    <arm_group_label>Treatment Sequence BDAC</arm_group_label>
    <arm_group_label>Treatment Sequence CABD</arm_group_label>
    <arm_group_label>Treatment Sequence DCBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral placebo</intervention_name>
    <description>Oral placebo (identical to 400 mg moxifloxacin)</description>
    <arm_group_label>Treatment Sequence ABCD</arm_group_label>
    <arm_group_label>Treatment Sequence BDAC</arm_group_label>
    <arm_group_label>Treatment Sequence CABD</arm_group_label>
    <arm_group_label>Treatment Sequence DCBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled prochlorperazine 5 mg</intervention_name>
    <description>Staccato prochlorperazine 5 mg, single dose</description>
    <arm_group_label>Treatment Sequence ABCD</arm_group_label>
    <arm_group_label>Treatment Sequence BDAC</arm_group_label>
    <arm_group_label>Treatment Sequence CABD</arm_group_label>
    <arm_group_label>Treatment Sequence DCBA</arm_group_label>
    <other_name>ADASUVE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled prochlorperazine 10 mg</intervention_name>
    <description>Inhaled prochlorperazine 10 mg, single dose</description>
    <arm_group_label>Treatment Sequence ABCD</arm_group_label>
    <arm_group_label>Treatment Sequence BDAC</arm_group_label>
    <arm_group_label>Treatment Sequence CABD</arm_group_label>
    <arm_group_label>Treatment Sequence DCBA</arm_group_label>
    <other_name>ADASUVE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral moxifloxacin</intervention_name>
    <description>Oral moxifloxacin 400 mg, si/ngle dose</description>
    <arm_group_label>Treatment Sequence ABCD</arm_group_label>
    <arm_group_label>Treatment Sequence BDAC</arm_group_label>
    <arm_group_label>Treatment Sequence CABD</arm_group_label>
    <arm_group_label>Treatment Sequence DCBA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects between the ages of 18 to 65 years, inclusive.

          2. Body mass index (BMI) ≥21 and ≤30.

          3. Subjects who are willing and able to comply with the study schedule and requirements,
             and stay at the CRU for a 3-day period and 3 consecutive 2-day periods.

          4. Subjects who speak, read, and understand English and are willing and able to provide
             written informed consent on an IRB approved form prior to the initiation of any study
             procedures.

          5. Subjects who are in good general health prior to study participation as determined by
             a detailed medical history, physical examination, 12-lead ECG, blood chemistry
             profile, hematology, urinalysis, and in the opinion of the Principal Investigator.

          6. Female participants (if of child-bearing potential and sexually active) and male
             participants (if sexually active with a partner of child-bearing potential) who agree
             to use a medically acceptable and effective birth control method throughout the study
             and for one week following the end of the study.

        Exclusion Criteria:

          1. Subjects who regularly consume large amounts of xanthine-containing substances must be
             excluded.

          2. Subjects who have taken prescription or nonprescription medication within 5 days of
             Treatment Period 1 must be excluded.

          3. Subjects who have had an acute illness within the last 5 days of Treatment Period 1
             must be excluded.

          4. Subjects who have smoked tobacco within the last year must be excluded.

          5. Subjects who have a history of HIV positivity must be excluded.

          6. Subjects who have a history of allergy or intolerance to prochlorperazine or
             phenothiazines must be excluded.

          7. Subjects who have a history of contraindication to anticholinergics must be excluded.

          8. Subjects who have a history of pheochromocytoma, seizure disorder, Parkinson's
             disease, or Restless Leg Syndrome must be excluded.

          9. Subjects who have an ECG abnormality must be excluded.

         10. Subjects who have a history within the past 2 years of drug or alcohol dependence or
             abuse as defined by DSM-4 must be excluded.

         11. Subjects who have a history of syncope, unstable angina, myocardial infarction (within
             6 months), congestive heart failure, transient ischemic attack, or pheochromocytoma
             must be excluded.

         12. Subjects who have a history of asthma or chronic obstructive lung disease must be
             excluded.

         13. Subjects who have hypotension (systolic ≤90 mmHg, diastolic ≤50 mmHg), or hypertension
             (systolic ≥140 mmHg, diastolic blood pressure ≥90 mmHg) must be excluded.

         14. Subjects who test positive for alcohol or have a positive urine drug screen must be
             excluded.

         15. Female subjects who have a positive pregnancy test at screening or during
             randomization visit, or are breastfeeding must be excluded.

         16. Subjects who have received an investigational drug within 30 days prior to the
             Screening Visit must be excluded.

         17. Subjects who are considered by the investigator, for any reason, to be an unsuitable
             candidate for receiving prochlorperazine, or unable to use the inhalation device, must
             be excluded.

         18. Subjects who have any other disease(s), by history, physical examination, or
             laboratory abnormalities (ALT or AST &gt; 2-fold the upper limit of normal, bilirubin &gt;
             1.5 mg/dL, or creatinine &gt; 1.8 mg/dL) or that in the investigator's opinion present
             undue risk to the subject or may confound the interpretation of study results must be
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall R Stoltz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance GFI Research, Evansville, IN 47714</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>October 10, 2007</study_first_submitted>
  <study_first_submitted_qc>October 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2007</study_first_posted>
  <results_first_submitted>March 10, 2017</results_first_submitted>
  <results_first_submitted_qc>November 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 11, 2019</results_first_posted>
  <last_update_submitted>November 19, 2018</last_update_submitted>
  <last_update_submitted_qc>November 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inhaled prochlorperazine, Thorough Qt/QTc,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Prochlorperazine</mesh_term>
    <mesh_term>Loxapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Eligible subjects reported to the CRU for baseline assessments (Day 1). The subjects were confined to the Clinical Research Unit under continuous medical or paramedical observation until at least 24 hours after each dose of Staccato Prochlorperazine or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence ABCD</title>
          <description>All subjects were to receive all 4 treatments in this 4 treatment crossover</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence BDAC</title>
          <description>All subjects were to receive all 4 treatments in this 4 treatment crossover</description>
        </group>
        <group group_id="P3">
          <title>Treatment Sequence CABD</title>
          <description>All subjects were to receive all 4 treatments in this 4 treatment crossover</description>
        </group>
        <group group_id="P4">
          <title>Treatment Sequence DCBA</title>
          <description>All subjects were to receive all 4 treatments in this 4 treatment crossover</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Safety Population</title>
          <description>All subjects were to receive all 4 treatments in this 4 treatment crossover</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.7" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Effect of Inhaled Prochlorperazine on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo</title>
        <description>Time-matched differences in QTcI values between the maximum of the mean difference from baseline of the QTcI interval after time-matched placebo subtraction for treatment at 11 post-inhalation times.</description>
        <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 22 hr</time_frame>
        <population>QT population -- LSM and CI statistics were based on the individual (within subject) corrected differences between prochlorperazine and placebo exposures per ICH Guideline E14 for a thorough QT/QTc study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Inhaled Prochlorperazine 5 mg Crossover Subjects</title>
            <description>All subjects who completed both treatments B and C: Treatment: B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo
The analyses are based on a within (paired) comparison of the time matched drug - placebo QTc values.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+Inhaled Prochlorperazine 10 mg Crossover Subjects</title>
            <description>All subjects who completed both treatments A and C: Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, C = Inhaled placebo + oral placebo.
The analyses are based on a within (paired) comparison of the time matched drug - placebo QTc values.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Effect of Inhaled Prochlorperazine on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo</title>
          <description>Time-matched differences in QTcI values between the maximum of the mean difference from baseline of the QTcI interval after time-matched placebo subtraction for treatment at 11 post-inhalation times.</description>
          <population>QT population -- LSM and CI statistics were based on the individual (within subject) corrected differences between prochlorperazine and placebo exposures per ICH Guideline E14 for a thorough QT/QTc study.</population>
          <units>milliseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.493" lower_limit="2.635" upper_limit="8.351"/>
                    <measurement group_id="O2" value="5.229" lower_limit="2.405" upper_limit="8.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTcI Versus Prochlorperazine Concentration</title>
        <description>QTcI @ median prochlorperazine concentration (3.75 mcg/mL) based on linear and nonlinear regression of QTcI versus time matched serum prochlorperazine concentrations</description>
        <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 22 hr</time_frame>
        <population>846 paired QTcI and prochlorperazine concentration pairs from 42 subjects receiving prochlorperazine (5 or 10 mg)
Each measure was based on the individual (within subject) corrected differences between prochlorperazine and placebo exposures per ICH Guideline E14 for a thorough QT study.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Prochlorperazine</title>
            <description>Serum concentrations following Staccato prochlorperazine 5 and 10 mg, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>QTcI Versus Prochlorperazine Concentration</title>
          <description>QTcI @ median prochlorperazine concentration (3.75 mcg/mL) based on linear and nonlinear regression of QTcI versus time matched serum prochlorperazine concentrations</description>
          <population>846 paired QTcI and prochlorperazine concentration pairs from 42 subjects receiving prochlorperazine (5 or 10 mg)
Each measure was based on the individual (within subject) corrected differences between prochlorperazine and placebo exposures per ICH Guideline E14 for a thorough QT study.</population>
          <units>milliseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" lower_limit="1.11" upper_limit="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers and % of Subjects With QTcI &gt; 450 ms</title>
        <description>Numbers and Percents of Subjects with QTcI exceeding 450 ms</description>
        <time_frame>24 hours</time_frame>
        <population>QT Population (placebo and prochlorperazine only)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled placebo Oral placebo
Inhaled placebo: Inhaled Staccato placebo (0 mg)
Oral placebo: Oral placebo (identical to 400 mg moxifloxacin)</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Prochlorperazine 5 mg</title>
            <description>Staccato prochlorperazine 5 mg, single dose Oral placebo
Oral placebo: Oral placebo (identical to 400 mg moxifloxacin)
Inhaled prochlorperazine 5 mg: Staccato prochlorperazine 5 mg, single dose</description>
          </group>
          <group group_id="O3">
            <title>Inhaled Prochlorperazine 10 mg</title>
            <description>Staccato prochlorperazine 10 mg, single dose Oral placebo
Oral placebo: Oral placebo (identical to 400 mg moxifloxacin)
Inhaled prochlorperazine 10 mg: Inhaled prochlorperazine 10 mg, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers and % of Subjects With QTcI &gt; 450 ms</title>
          <description>Numbers and Percents of Subjects with QTcI exceeding 450 ms</description>
          <population>QT Population (placebo and prochlorperazine only)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers and % of Subjects With QTcI &gt; 480 ms</title>
        <description>Numbers and Percents of Subjects with QTcI exceeding 480 ms at any of the outcome measure time points</description>
        <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 22 hr</time_frame>
        <population>QT population -- LSM and CI statistics were based on the individual (within subject) corrected differences between active and placebo exposures per ICH Guideline E14 for a thorough</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled placebo + Oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Prochlorperazine 5 mg</title>
            <description>Staccato prochlorperazine 5 mg, single dose Oral placebo</description>
          </group>
          <group group_id="O3">
            <title>Inhaled Prochlorperazine 10 mg</title>
            <description>Inhaled prochlorperazine 10 mg: Inhaled prochlorperazine 10 mg, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers and % of Subjects With QTcI &gt; 480 ms</title>
          <description>Numbers and Percents of Subjects with QTcI exceeding 480 ms at any of the outcome measure time points</description>
          <population>QT population -- LSM and CI statistics were based on the individual (within subject) corrected differences between active and placebo exposures per ICH Guideline E14 for a thorough</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers and % of Subjects With QTcI Change &gt; 30 ms</title>
        <description>Numbers and Percents of Subjects with QTcI increase from baseline exceeding 30 ms at any of the outcome measure time points</description>
        <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 22 hr</time_frame>
        <population>QT population -- LSM and CI statistics were based on the individual (within subject) corrected differences between active and placebo exposures per ICH Guideline E14 for a thorough QT/QTc study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled placebo + Oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Prochlorperazine 5 mg</title>
            <description>Staccato prochlorperazine 5 mg, single dose + Oral placebo</description>
          </group>
          <group group_id="O3">
            <title>Inhaled Prochlorperazine 10 mg</title>
            <description>Inhaled prochlorperazine 10 mg: Inhaled prochlorperazine 10 mg, single dose + Oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers and % of Subjects With QTcI Change &gt; 30 ms</title>
          <description>Numbers and Percents of Subjects with QTcI increase from baseline exceeding 30 ms at any of the outcome measure time points</description>
          <population>QT population -- LSM and CI statistics were based on the individual (within subject) corrected differences between active and placebo exposures per ICH Guideline E14 for a thorough QT/QTc study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers and % of Subjects With QTcI Change &gt; 60 ms</title>
        <description>Numbers and Percents of Subjects with QTcI increase from baseline exceeding 60 ms at any of the outcome measure time points</description>
        <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 22 hr</time_frame>
        <population>QT population -- LSM and CI statistics were based on the individual (within subject) corrected differences between active and placebo exposures per ICH Guideline E14 for a thorough QT/QTc study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled placebo + Oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Prochlorperazine 5 mg</title>
            <description>Staccato prochlorperazine 5 mg, single dose + Oral placebo</description>
          </group>
          <group group_id="O3">
            <title>Inhaled Prochlorperazine 10 mg</title>
            <description>Inhaled prochlorperazine 10 mg: Inhaled prochlorperazine 10 mg, single dose + Oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers and % of Subjects With QTcI Change &gt; 60 ms</title>
          <description>Numbers and Percents of Subjects with QTcI increase from baseline exceeding 60 ms at any of the outcome measure time points</description>
          <population>QT population -- LSM and CI statistics were based on the individual (within subject) corrected differences between active and placebo exposures per ICH Guideline E14 for a thorough QT/QTc study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity)</title>
        <description>A thorough QT/QTc study may be considered to have demonstrated assay sensitivity if 1 or more of the lower 95% CI values exceeds 5 msec</description>
        <time_frame>1, 1.5, 2, 2.5, 3, 5 hours</time_frame>
        <population>QT population -- LSM and CI statistics were based on the individual (within subject) corrected differences between moxifloxacin and placebo exposures per ICH Guideline E14 for a thorough QT study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Oral Moxifloxacin 400 mg Crossover Subjects</title>
            <description>All subjects who completed both treatments C and D: Treatment: C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
The analyses are based on a within (paired) comparison of the time matched drug - placebo QTc values.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity)</title>
          <description>A thorough QT/QTc study may be considered to have demonstrated assay sensitivity if 1 or more of the lower 95% CI values exceeds 5 msec</description>
          <population>QT population -- LSM and CI statistics were based on the individual (within subject) corrected differences between moxifloxacin and placebo exposures per ICH Guideline E14 for a thorough QT study.</population>
          <units>milliseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.595" lower_limit="6.062" upper_limit="13.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were considered treatment related from the first exposure to study treatment until 30 days after the last treatment</time_frame>
      <desc>Adverse events (AEs) were assessed predose and at 14 pre-specified time points as well as whenever spontaneously reported by the subjects or study staff</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Inhaled placebo Oral placebo
Inhaled placebo: Inhaled Staccato placebo (0 mg)
Oral placebo: Oral placebo (identical to 400 mg moxifloxacin)</description>
        </group>
        <group group_id="E2">
          <title>Inhaled Prochlorperazine 5 mg</title>
          <description>Staccato prochlorperazine 5 mg, single dose Oral placebo
Oral placebo: Oral placebo (identical to 400 mg moxifloxacin)
Inhaled prochlorperazine 5 mg: Staccato prochlorperazine 5 mg, single dose</description>
        </group>
        <group group_id="E3">
          <title>Inhaled Prochlorperazine 10 mg</title>
          <description>Staccato prochlorperazine 10 mg, single dose Oral placebo
Oral placebo: Oral placebo (identical to 400 mg moxifloxacin)
Inhaled prochlorperazine 10 mg: Inhaled prochlorperazine 10 mg, single dose</description>
        </group>
        <group group_id="E4">
          <title>Oral Moxifloxacin 400 mg</title>
          <description>Oral moxifloxacin 400 mg Inhaled placebo
Inhaled placebo: Inhaled Staccato placebo (0 mg)
Oral moxifloxacin: Oral moxifloxacin 400 mg, si/ngle dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="46"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The use of healthy subjects precludes observation of drug-induced QTc prolongation in a population with additional factors predisposing to TdP. Subjects with respiratory disease were excluded.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Executive VP, Research &amp; Development, Regulatory &amp; Quality</name_or_title>
      <organization>Alexza Pharmaceuticals, Inc</organization>
      <phone>650.944.7071</phone>
      <email>ClinicalTrialsInfo@alexza.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

